A 23-gene multi-omics signature predicts prognosis and treatment response in non-small cell lung cancer

Abstract Background We developed the first multi-omics prognostic signature integrating 19 programmed cell death (PCD) pathways and organelle functions (mitochondria, lysosomes, Golgi apparatus) to predict prognosis and immunotherapy response in non-small cell lung cancer (NSCLC). (2) Methods: By co...

Full description

Saved in:
Bibliographic Details
Main Authors: Yinxu Zhang, Siwang Wang, Xiaoyang Chen, Guangyu Zhang, Yuxi Wang, Xiaomei Liu
Format: Article
Language:English
Published: Springer 2025-07-01
Series:Discover Oncology
Subjects:
Online Access:https://doi.org/10.1007/s12672-025-03243-2
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849343454688051200
author Yinxu Zhang
Siwang Wang
Xiaoyang Chen
Guangyu Zhang
Yuxi Wang
Xiaomei Liu
author_facet Yinxu Zhang
Siwang Wang
Xiaoyang Chen
Guangyu Zhang
Yuxi Wang
Xiaomei Liu
author_sort Yinxu Zhang
collection DOAJ
description Abstract Background We developed the first multi-omics prognostic signature integrating 19 programmed cell death (PCD) pathways and organelle functions (mitochondria, lysosomes, Golgi apparatus) to predict prognosis and immunotherapy response in non-small cell lung cancer (NSCLC). (2) Methods: By combining single-cell RNA-seq, bulk transcriptomics, and deep neural networks (DNN), we identified a 23-gene signature validated across four cohorts (AUC 0.696–0.812). Conducted MR analysis to explore causal links between signature genes and NSCLC incidence, providing biological insights. (3) Results: A prognostic signature was developed, including 23 prognostic genes related to 19 PCD patterns and three organelle functions. The signature demonstrated powerful performance in predicting NSCLC prognosis, immune in-filtration, and therapeutic response. Established DNN models showed high value in predicting risk score groupings of NSCLC. MR analysis for combined SNP information of the 23 prognostic genes suggested a link to the high incidence of NSCLC. Individual MR analysis showed that HIF1A and SQLE expression had a causal effect on NSCLC incidence. (4) Conclusion: This signature stratifies high-risk patients with immunosuppressive microenvironments and predicts enhanced sensitivity to gemcitabine and PD-1 inhibitors, offering a roadmap for personalized NSCLC management.
format Article
id doaj-art-7a8c554d583b4f70adf66f6cf6da4e10
institution Kabale University
issn 2730-6011
language English
publishDate 2025-07-01
publisher Springer
record_format Article
series Discover Oncology
spelling doaj-art-7a8c554d583b4f70adf66f6cf6da4e102025-08-20T03:42:57ZengSpringerDiscover Oncology2730-60112025-07-0116112410.1007/s12672-025-03243-2A 23-gene multi-omics signature predicts prognosis and treatment response in non-small cell lung cancerYinxu Zhang0Siwang Wang1Xiaoyang Chen2Guangyu Zhang3Yuxi Wang4Xiaomei Liu5Department of Surgery, The First Affiliated Hospital of Jinzhou Medical UniversityDepartment of Surgery, The First Affiliated Hospital of Jinzhou Medical UniversityDepartment of Oncology, The First Affiliated Hospital of Jinzhou Medical UniversityDepartment of Oncology, The First Affiliated Hospital of Jinzhou Medical UniversityDepartment of Oncology, The First Affiliated Hospital of Jinzhou Medical UniversityDepartment of Oncology, The First Affiliated Hospital of Jinzhou Medical UniversityAbstract Background We developed the first multi-omics prognostic signature integrating 19 programmed cell death (PCD) pathways and organelle functions (mitochondria, lysosomes, Golgi apparatus) to predict prognosis and immunotherapy response in non-small cell lung cancer (NSCLC). (2) Methods: By combining single-cell RNA-seq, bulk transcriptomics, and deep neural networks (DNN), we identified a 23-gene signature validated across four cohorts (AUC 0.696–0.812). Conducted MR analysis to explore causal links between signature genes and NSCLC incidence, providing biological insights. (3) Results: A prognostic signature was developed, including 23 prognostic genes related to 19 PCD patterns and three organelle functions. The signature demonstrated powerful performance in predicting NSCLC prognosis, immune in-filtration, and therapeutic response. Established DNN models showed high value in predicting risk score groupings of NSCLC. MR analysis for combined SNP information of the 23 prognostic genes suggested a link to the high incidence of NSCLC. Individual MR analysis showed that HIF1A and SQLE expression had a causal effect on NSCLC incidence. (4) Conclusion: This signature stratifies high-risk patients with immunosuppressive microenvironments and predicts enhanced sensitivity to gemcitabine and PD-1 inhibitors, offering a roadmap for personalized NSCLC management.https://doi.org/10.1007/s12672-025-03243-2Non-small cell lung cancerProgrammed cell deathOrganelle functionSingle-cell analysisMachine learningPrognosis
spellingShingle Yinxu Zhang
Siwang Wang
Xiaoyang Chen
Guangyu Zhang
Yuxi Wang
Xiaomei Liu
A 23-gene multi-omics signature predicts prognosis and treatment response in non-small cell lung cancer
Discover Oncology
Non-small cell lung cancer
Programmed cell death
Organelle function
Single-cell analysis
Machine learning
Prognosis
title A 23-gene multi-omics signature predicts prognosis and treatment response in non-small cell lung cancer
title_full A 23-gene multi-omics signature predicts prognosis and treatment response in non-small cell lung cancer
title_fullStr A 23-gene multi-omics signature predicts prognosis and treatment response in non-small cell lung cancer
title_full_unstemmed A 23-gene multi-omics signature predicts prognosis and treatment response in non-small cell lung cancer
title_short A 23-gene multi-omics signature predicts prognosis and treatment response in non-small cell lung cancer
title_sort 23 gene multi omics signature predicts prognosis and treatment response in non small cell lung cancer
topic Non-small cell lung cancer
Programmed cell death
Organelle function
Single-cell analysis
Machine learning
Prognosis
url https://doi.org/10.1007/s12672-025-03243-2
work_keys_str_mv AT yinxuzhang a23genemultiomicssignaturepredictsprognosisandtreatmentresponseinnonsmallcelllungcancer
AT siwangwang a23genemultiomicssignaturepredictsprognosisandtreatmentresponseinnonsmallcelllungcancer
AT xiaoyangchen a23genemultiomicssignaturepredictsprognosisandtreatmentresponseinnonsmallcelllungcancer
AT guangyuzhang a23genemultiomicssignaturepredictsprognosisandtreatmentresponseinnonsmallcelllungcancer
AT yuxiwang a23genemultiomicssignaturepredictsprognosisandtreatmentresponseinnonsmallcelllungcancer
AT xiaomeiliu a23genemultiomicssignaturepredictsprognosisandtreatmentresponseinnonsmallcelllungcancer
AT yinxuzhang 23genemultiomicssignaturepredictsprognosisandtreatmentresponseinnonsmallcelllungcancer
AT siwangwang 23genemultiomicssignaturepredictsprognosisandtreatmentresponseinnonsmallcelllungcancer
AT xiaoyangchen 23genemultiomicssignaturepredictsprognosisandtreatmentresponseinnonsmallcelllungcancer
AT guangyuzhang 23genemultiomicssignaturepredictsprognosisandtreatmentresponseinnonsmallcelllungcancer
AT yuxiwang 23genemultiomicssignaturepredictsprognosisandtreatmentresponseinnonsmallcelllungcancer
AT xiaomeiliu 23genemultiomicssignaturepredictsprognosisandtreatmentresponseinnonsmallcelllungcancer